Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2019-10-23 Annual Report
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Annual Report and Notice of AGM 62 pages 3.0MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report and Notice of AGM' and explicitly states it is the Company's Annual Report for the year ended 30 June 2019. It contains detailed sections typical of an annual report, including Operating and Financial Review, Corporate Governance Statement, Directors’ Report, Auditor’s Report, and Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial and operational information, clinical trial results, corporate governance, and patent status, consistent with an Annual Report (10-K equivalent). Therefore, the document is classified as an Annual Report (10-K).
2019-10-23 English
Appendix 4C - quarterly 5 pages 717.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 30 September 2019. It includes sections on cash flows from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to directors and related parties, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document is approximately 8,860 characters long, which is sufficient to contain substantive financial data rather than just an announcement or certification. The content aligns with a quarterly financial report providing comprehensive financial data for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2019-10-20 English
Appendix 3B 13 pages 1.4MB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities submitted to the ASX (Australian Securities Exchange). It details the issuance of new fully paid ordinary shares, the number of securities issued, issue price, and compliance with ASX Listing Rules. The document includes sections on quotation agreements and calculation of placement capacity under ASX rules. It is a regulatory announcement about new share issuance and quotation application, not a financial report or earnings release. The document length is substantial and contains detailed information about the share issue, but it is not a financial report or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-10-07 English
Appointment of International Advisory Board for BIT225 2 pages 130.2KB
Board/Management Information Classification · 95% confidence The document is a short announcement dated 1 October 2019 from Biotron Limited regarding the appointment of an International Advisory Board for its HIV-1 clinical development program. It includes details about the members of the Scientific Advisory Board and their credentials. There are no financial statements, regulatory filings, or detailed reports included. The document is only 4169 characters long and serves as a notification of a board-related appointment rather than a full management or board report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management, including advisory board appointments.
2019-09-30 English
Appendix 3B 13 pages 1.4MB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities filed with the ASX. It details the issuance of 68,000 fully paid ordinary shares, the exercise of options, and compliance with ASX Listing Rules. The document includes sections on the class and number of securities issued, issue price, purpose, quotation agreement, and calculation of placement capacity under ASX rules. It is a regulatory announcement about new share issuance and related securities quotation, not a financial report or earnings release. The document length is substantial and contains detailed information about the securities issuance, but it is not a financial statement or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-09-18 English
Full Year Statutory Accounts 52 pages 1.1MB
Annual Report Classification · 100% confidence The document is titled 'YEAR END ACCOUNTS AND PRELIMINARY FINAL REPORT' and includes an Appendix 4E Preliminary Final Report for the year ended 30 June 2019. It references the attached Annual Report which forms part of this Preliminary Final Report. The document contains detailed financial statements, operating and financial review, directors' report, auditor's report, and other comprehensive financial information typical of an Annual Report. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is the full Annual Report for the fiscal year ending 30 June 2019.
2019-08-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.